This article is a collaboration between MedPage Today and:
A novel liver dialysis device for patients with acute on chronic liver failure (ACLF) was safe compared to standard of care, a small randomized study found.
In a European multi-center trial of 32 patients, serious adverse events occurred in 11 patients treated with the Dialive extracorporeal liver assist device versus in eight patients receiving standard of care. Deaths in both groups were also comparable (four and three, respectively), reported Banwari Agarwal, MD, of Royal Free Hospital in London.
While efficacy was not the purpose of the study, data from this small group also found that the intervention was associated with improvements in organ function, and ACLF-free survival compared to standard of care.
Yaqrit Discovery Ltd: Top liver disease conference showcases positive clinical data from Yaqrit s technologies
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Investegate |Yaqrit Discovery Ltd Announcements | Yaqrit Discovery Ltd: Top liver disease conference showcases positive clinical data from Yaqrit s technologies
investegate.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investegate.co.uk Daily Mail and Mail on Sunday newspapers.
Top liver disease conference showcases positive clinical
globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.